CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $1,552,500.00 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $51.75, for a total transaction of $1,552,500.00. Following the completion of the sale, the chief executive officer directly owned 194,201 shares in the company, valued at approximately $10,049,901.75. This trade represents a 13.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Samarth Kulkarni also recently made the following trade(s):

• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Trading Down 8.7%

CRISPR Therapeutics stock opened at $55.52 on Friday. The firm has a 50 day simple moving average of $54.94 and a 200 day simple moving average of $58.41. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The firm has a market capitalization of $5.29 billion, a price-to-earnings ratio of -9.93 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.17) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. The firm had revenue of $0.89 million during the quarter, compared to analyst estimates of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CRSP shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday. Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating on the stock in a report on Wednesday, November 26th. Citigroup reiterated a “buy” rating and issued a $77.00 target price (down from $87.00) on shares of CRISPR Therapeutics in a research note on Tuesday, November 11th. Bank of America reduced their price target on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Wedbush decreased their price target on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a report on Wednesday, November 5th. Twelve investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $68.15.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Thurston Springer Miller Herd & Titak Inc. raised its position in CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of CRISPR Therapeutics during the 2nd quarter valued at about $33,000. Thompson Investment Management Inc. purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at about $33,000. Optiver Holding B.V. lifted its position in CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the last quarter. Finally, Strategic Advocates LLC bought a new stake in CRISPR Therapeutics in the 3rd quarter worth approximately $34,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.